Tag archive for ‘AB generic to EpiPen approval’
Antares: Things Are Looking Up (ATRS, Buy, $2.22)
Overview of Report I listened to the presentation by CEO Bob Apple at the Raymond James conference on March 5th and go over his key remarks in this report I have been frustrated by the CRL for Xyosted and delays in approval for AB rated versions of EpiPen and Byetta which have had a sharply […]